Medical Aesthetics: A Untapped Pharma Market With Incoming Competition

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.

Anti-aging aesthetic medical treatment. 3d illustration of plastic surgery.Mesh and lines in the skin and procedure to eliminate wrinkles
One of biggest challenges for all biopharma players in medical aesthetics is to grow overall market • Source: Shutterstock

Allergan PLC is the dominant player in medical aesthetics with its blockbuster wrinkle-reducing neurotoxin Botox (onabotulinumtoxinA) and portfolio of injectables, implants and other products, but it is not alone. Merz Pharmaceuticals GMBH and Galderma SA also have spent years curating collections of products to entice doctors who are seeing surging interest from patients in non-invasive procedures to improve their appearance.

One of the biggest challenges for all biopharma players in medical aesthetics is to grow the overall market. Allergan's research...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains